The @IMFmyeloma is in Cleveland this weekend for its Patient & Family Seminar. If you or a loved one has #myeloma please join us for this free program. Knowledge is Power. @jmikhaelmd@imfmikemyeloma @midatlantismsg https://t.co/JykOGOVCJP
You may already be using AI in your healthcare.
Where should it help and where should people lead care decisions?
Your input will shape tools for myeloma support.
Read more and take the survey: https://t.co/A91Tkx6YL2
In August, we’re riding across Iceland for every person who has heard the words, “you have myeloma.”
We ride for progress. Support our cyclists and help fund critical research: https://t.co/DNc7BVbXqQ
@szusmani#MyelomaIceland
A new oral drug shows promise for one of the most aggressive forms of myeloma. At #ASH25, IMF Scientific Advisory Board member Dr.@szusmani shared early results on KTX-1001, a therapy targeting a high-risk genetic driver of myeloma.
https://t.co/oQzvS13Vw5
#IMFSAB#IMFASH25
IMF research shows acting early in smoldering myeloma may help stop cancer before it starts. Results from the GEM-CESAR study highlight how early treatment and close monitoring can protect patients and quality of life. https://t.co/oQzvS13Vw5
#IMFSAB#IMFASH25#ASH25#IMFBSRI
How can multiple myeloma patients manage their pain? Dr. @jmikhaelmd, Chief Medical Officer of the International Myeloma Foundation, breaks down practical, patient-focused strategies to help manage myeloma-related pain in this one-minute video.
The International Myeloma Foundation announced that Heather Cooper Ortner has been named as the IMF's new President and Chief Executive Officer. https://t.co/Ez4it30SYy #CancerNews@IMFmyeloma
For the first time, people with high-risk smoldering myeloma can be treated before the disease becomes active cancer. Results from the AQUILA trial helped lead to FDA approval of early treatment.
https://t.co/oQzvS13Vw5
#IMFSAB#IMFASH25#ASH25
#ASH25 isn’t just where data is shared, it’s where pt's lives are shaped. Pt voices at ASH connects the pts to the science and the science to the pts! We help turn that data into HOPE for our fellow pts! Thank you #IMFASH25 for a great conference! #myeloma#mmsm@jmikhaelmd
My biggest takeaway from #ASH25 would be hope given to the Myeloma Voices at ASH team and all MM pts. New txs like the "in vivo" CAR-T results from inMMyCAR study and combo of Tec & Dara in the MajecTEC-3 study. Hope is our biggest gift! #IMFASH25@IMFmyeloma@jmikhaelmd#mmsm
Wishing all the #MYELOMA people a HAPPY...MERRY...HOLIDAY and a peaceful New Year! In the season of HOPE this myeloma patient thanks you all for the hope we feel from your continued dedication! #IMFASH25#IMF25@mmsm@jmikhaelmd
Let's make it our New Year's resolution to get informed! Join us in 2026 for a free IMF educational event for access to #myeloma experts, unparalleled myeloma education, and camaraderie with your community. Find an event near you or online: https://t.co/zZHxb9UK7H
@Bethfaiman
Join us for a free educational event near you or online! Our seminars and workshops offer exceptional myeloma education, unparalleled access to experts, and connection with others in your community. Find an event today at https://t.co/zZHxb9UK7H
@Bethfaiman
What’s New in Myeloma Research? Join our speakers online on Wednesday, January 7, 2026, to hear about the top myeloma research presented at ASH— all from a patient perspective. Register before spots are gone: https://t.co/yUotuVsCHI
#IMFASH25#ASH25#mmsm
Fascinating abstract examining whether ALC, a routinely measured lab, can serve as a predictor of delayed neurotoxicity following CAR-T therapy in MM. Nice to see research looking to improve CAR-T safety for us patients! #IMFASH25#ASH25#myeloma#mmsm
https://t.co/UpSF1XZmZP